COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year

Area of Science:

• Internal Medicine
• Cardiology
• Infectious Diseases

Background:

• COVID-19 presents a high risk of thrombotic complications due to unique interactions with endothelial cells, inflammation, and coagulation.
• Current guidelines for thrombosis prophylaxis in hospitalized COVID-19 patients lack robust evidence, leading to weak recommendations.

Purpose of the Study:

• To summarize the pathophysiology of COVID-19-associated coagulopathy across different patient groups (ambulant, hospitalized non-critically ill, critically ill, post-discharge).
• To review recent randomized controlled trial data on antithrombotic therapy in critically ill COVID-19 patients.
• To provide evidence-based recommendations for optimal antithrombotic use in COVID-19.

Main Methods:

• Review of the pathophysiology of COVID-19 coagulopathy.
• Analysis of data from randomized controlled trials (RCTs) evaluating antithrombotic therapy in COVID-19 patients.
• Synthesis of evidence for different patient strata: ambulant, hospitalized (non-critically and critically ill), and post-discharge.

Main Results:

• Pharmacological thromboprophylaxis is not routinely recommended for ambulant and post-discharge COVID-19 patients.
• A therapeutic dose of low-molecular-weight heparin may improve outcomes in non-critically ill hospitalized patients.
• Prophylactic dose anticoagulation is recommended for critically ill hospitalized patients, as therapeutic doses do not improve outcomes.

Conclusions:

• Optimal antithrombotic strategies for COVID-19 vary significantly based on disease severity and hospitalization status.
• New RCT data are crucial for refining clinical guidance on antithrombotic therapy for COVID-19 patients.
• Further research is expected to provide more definitive recommendations for managing COVID-19-associated coagulopathy.